Weight LossNot FDA ApprovedClinical Trials

HGH Fragment 176-191

Also known as Frag 176-191, HGH Frag, AOD-9401

The lipolytic fragment of human growth hormone. Contains the fat-burning portion of HGH without effects on blood sugar or cell proliferation.

Investigational - Research ongoing

Regulatory Pathway

Preclinical
Phase I
Phase II
Phase III
Phase IV
Approved

Dosing Protocol

Typical Dose

250-500 mcg daily

Frequency

1-2x daily, fasted

Duration

8-12 weeks

Community-reported dosing. Individual results vary. Not a medical recommendation.
Typical community protocol: 250-500 mcg daily via Subcutaneous injection on empty stomach, 1-2x daily, fasted. Dose range: 200-600 mcg daily. Duration: 8-12 weeks.

Timing & Administration

Administer via Subcutaneous injection on empty stomach. Frequency: 1-2x daily, fasted.

Mechanism of Action

Mimics the way natural HGH regulates fat metabolism but without adverse effects on blood sugar or growth. Stimulates lipolysis and inhibits lipogenesis, specifically targeting adipose tissue.

Research Summary

Evidence level: clinical trials. Clinical status: Investigational - Research ongoing.

Side Effects & Safety

Important Warnings

  • Does NOT cause typical HGH side effects
  • No effect on IGF-1 levels
  • GRAS status.
Injection site reactions
mild headache
nausea

References

No references available.